Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

Página do item simplificado
dc.creatorLigia Yukie Sassaki
dc.creatorMarley Ribeiro Feitosa
dc.creatorCarlos Henrique Marques Dos Santos
dc.creatorManoel Alvaro de Freitas Lins Neto
dc.creatorAbel Botelho Quaresma
dc.creatorSergio Figueiredo de Lima Junior
dc.creatorGraciana Bandeira Salgado de Vasconcelos
dc.creatorOrnella Sari Cassol
dc.creatorArlene Dos Santos Pinto
dc.creatorGustavo Kurachi
dc.creatorFrancisco de Assis Goncalves Filho
dc.creatorDaniela Oliveira Magro
dc.creatorRodrigo Galhardi Gasparini
dc.creatorThaísa Kowalski Furlan
dc.creatorWilson Roberto Catapani
dc.creatorCláudio Saddy Rodrigues Coy
dc.creatorVivian de Souza Menegassi
dc.creatorMarilia Majeski Colombo
dc.creatorRenata de sá Brito Fróes
dc.creatorFabio Vieira Teixeira
dc.creatorAntonio Carlos Moraes
dc.creatorGenoile Oliveira Santana
dc.creatorRogerio Saad-hossne
dc.creatorJosé Miguel Luz Parente
dc.creatorEduardo Garcia Vilela
dc.creatorNatália Sousa Freitas Queiroz
dc.creatorPaulo Gustavo Kotze
dc.creatorJulio Pinheiro Baima
dc.creatorCristina Flores
dc.creatorLucianna Motta Correia
dc.creatorLívia Medeiros Soares Celani
dc.creatorMaria de Lourdes de Abreu Ferrari
dc.creatorPatricia Zacharias
dc.date.accessioned2023-12-07T21:25:38Z
dc.date.accessioned2025-09-08T23:46:50Z
dc.date.available2023-12-07T21:25:38Z
dc.date.issued2022-05-29
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1186/s12876-022-02341-7
dc.identifier.issn1471-230X
dc.identifier.urihttps://hdl.handle.net/1843/61841
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofBMC Gastroenterology
dc.rightsAcesso Aberto
dc.subjectColite Ulcerativa
dc.subjectAdalimumab
dc.subjectBrasil
dc.subject.otherAnti-TNF therapy
dc.subject.otherAdalimumab
dc.subject.otherInfiximab
dc.subject.otherClinical remission
dc.subject.otherUlcerative colitis
dc.titleAnti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
dc.typeArtigo de periódico
local.citation.epage12
local.citation.issue268
local.citation.spage1
local.citation.volume22
local.description.resumoBackground Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The present study aimed to analyze rates of clinical and endoscopic remission comparatively, between adalimumab (ADA) and infliximab (IFX), in Brazilian patients with UC, and evaluate factors associated with clinical and endoscopic remission after 1 year of treatment. Methods A national retrospective multicenter study (24 centers) was performed including patients with UC treated with anti-TNF therapy. Outcomes as clinical response and remission, endoscopic remission and secondary loss of response were measured in different time points of the follow-up. Baseline predictive factors of clinical and endoscopic remission at week 52 were evaluated using logistic regression model. Indirect comparisons among groups (ADA and IFX) were performed using Student's t, Pearson χ2 or Fisher's exact test when appropriated, and Kaplan Meier analysis. Results Overall, 393 patients were included (ADA, n = 111; IFX, n = 282). The mean age was 41.86 ± 13.60 years, 61.58% were female, most patients had extensive colitis (62.40%) and 19.39% had previous exposure to a biological agent. Overall, clinical remission rate was 66.78%, 71.62% and 82.82% at weeks 8, 26 and 52, respectively. Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan–Meier survival curve loss of response was less frequent in the Infliximab compared to Adalimumab group (p = 0.001). Overall, endoscopic remission was observed in 50% of patients at week 26 and in 65.98% at week 52, with no difference between the groups (p = 0.114). Colectomy was performed in 23 patients (5.99%). Age, non-prior exposure to biological therapy, use of IFX and endoscopic remission at week 26 were associated with clinical remission after 52 weeks. Variables associated with endoscopic remission were non-prior exposure to biological therapy, and clinical and endoscopic remission at week 26. Conclusions IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission.
local.identifier.orcidhttp://orcid.org/0000-0002-7319-8906
local.identifier.orcidhttp://orcid.org/0000-0002-8180-6254
local.identifier.orcidhttp://orcid.org/0000-0002-8166-0304
local.identifier.orcidhttp://orcid.org/0000-0002-4035-3113
local.identifier.orcidhttp://orcid.org/0000-0003-1623-4525
local.identifier.orcidhttp://orcid.org/0000-0002-5621-2657
local.identifier.orcidhttp://orcid.org/0000-0002-2122-5538
local.identifier.orcidhttp://orcid.org/0000-0002-7890-0848
local.identifier.orcidhttp://orcid.org/0000-0002-4440-2023
local.identifier.orcidhttp://orcid.org/0000-0002-1181-7329
local.identifier.orcidhttp://orcid.org/0000-0003-1903-844X
local.identifier.orcidhttp://orcid.org/0000-0002-3985-7402
local.identifier.orcidhttp://orcid.org/0000-0002-1250-2628
local.identifier.orcidhttp://orcid.org/0000-0002-2132-8780
local.identifier.orcidhttp://orcid.org/0000-0003-0867-6593
local.identifier.orcidhttp://orcid.org/0000-0001-7509-7730
local.identifier.orcidhttp://orcid.org/0000-0003-0344-9631
local.identifier.orcidhttp://orcid.org/0000-0003-0153-4349
local.identifier.orcidhttp://orcid.org/0000-0002-1032-5349
local.identifier.orcidhttp://orcid.org/0000-0002-9516-0378
local.identifier.orcidhttp://orcid.org/0000-0002-0412-2182
local.identifier.orcidhttp://orcid.org/0000-0002-0916-4138
local.identifier.orcidhttp://orcid.org/0000-0003-3046-2399
local.identifier.orcidhttp://orcid.org/0000-0001-6684-8061
local.identifier.orcidhttp://orcid.org/0000-0003-3256-4698
local.identifier.orcidhttp://orcid.org/0000-0002-8915-7279
local.identifier.orcidhttp://orcid.org/0000-0002-5533-5401
local.identifier.orcidhttp://orcid.org/0000-0003-4563-2784
local.identifier.orcidhttp://orcid.org/0000-0002-5443-7553
local.identifier.orcidhttp://orcid.org/0000-0003-2857-0825
local.identifier.orcidhttp://orcid.org/0000-0002-2053-5315
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02341-7

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Anti-TNF therapy for ulcerative colitis in Brazil_ a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).pdf
Tamanho:
328.19 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG